TGTX 250509 36.00C(TGTX250509C36000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

TGTX250509C36000

Watchlist

2.39
-7.06-74.71%

15min DelayClose May 5 16:00 ET

3.00High1.40Low

Intraday

5D
Daily

News

TD Cowen Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $50
Moomoo News03:31 ET · Ratings
Jefferies Maintains TG Therapeutics(TGTX.US) With Buy Rating, Maintains Target Price $46
Moomoo News03:31 ET · Ratings
Q1 2025 TG Therapeutics Inc Earnings Call
Yahoo Finance23:20 ET
Top Gap Ups and Downs on Monday: BRK.A, BRK.B, BBVA and More
Moomoo News18:00 ET · Markets
Why TG Therapeutics Stock Was Tumbling Today
Yahoo Finance15:37 ET
TG Therapeutics Down Over 15%, on Track for Largest Percent Decrease Since August 2023 -- Data Talk
Dow Jones14:03 ET

Comments

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

$TG Therapeutics (TGTX.US)$
TG Therapeutics Crushes Earnings: MS Drug BRIUMVI Drives 137% Growth, Company Turns Profitable

TG Therapeutics Reports First Quarter 2025 Financial Results and Raises BRIUMVI Full Year Revenue Guidance

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

$TG Therapeutics (TGTX.US)$
Game-Changing MS Treatment? BRIUMVI Single-Dose Trial Reveals Breakthrough Potential

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

$TG Therapeutics (TGTX.US)$
Game-Changing MS Treatment: BRIUMVI Reveals Exceptional Real-World Safety Profile

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2025 Annual Meeting

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

$TG Therapeutics (TGTX.US)$
Medical Journals Reveal Breakthrough: BRIUMVI Succeeds Where Other MS Treatments Fall Short

TG Therapeutics Announces Two Publications Highlighting BRIUMVI in Medical Journals

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

$TG Therapeutics (TGTX.US)$
How TG Therapeutics Transformed from Clinical-Stage to Profitable Biotech with 250% Revenue Growth

TG Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Read more